Concepedia

Sharon Aslanian

SA

Statistics

Publications

4

Citations

330

H-Index

4

Active since

2010

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Sharon Aslanian is an author at The University of Texas MD Anderson Cancer Center specializing in cell biology, tumor microenvironment, and immunology.

Top concepts

Publications per year

2010–2013

4

Publications

4

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Erica N Evans, Richland Tester, Sharon Aslanian et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 219 citations

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Roni Mamluk, Irvith M. Carvajal, Brent Morse et al. · mAbs · 2010 · 79 citations · Full text

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

Erica N Evans, Richland Tester, Sharon Aslanian et al. · Blood · 2011 · 20 citations

2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth

Erica N Evans, Sabine Ponader, Russell Karp et al. · Clinical Lymphoma Myeloma & Leukemia · 2011 · 12 citations

, , +6

Rows per page

1–4 of 4